fbpx
Wikipedia

CSL Vifor

January 26, 2023

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

CSL Vifor
TypePublic
SIX: VIFN
ISINCH0364749348
IndustryPharmaceutical
Founded1927[1]
Headquarters
Switzerland
Areas served
Worldwide
Key people
Hervé Gisserot (General Manager)[2]
Revenue CHF 1.75 billion (2021)[3]
Websitewww.viforpharma.com

History

  • In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen
  • In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933 (later to be renamed Vifor Pharma Ltd. in 2017)
  • In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines
  • In 1983, Hausmann AG laboratories is acquired by Galenica
  • In 1991, Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products
  • In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation,[4] Vifor Ltd. and Vifor (international) Ltd. are integrated in Vifor Pharma.
  • In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company
  • In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
  • In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé
  • In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion[5]
  • In 2017, the IPO of Galenica Santé (GALE) is completed and listed on the Swiss Stock Exchange. Galenica AG (GALE) and Vifor Pharma AG (VIFN) are listed as independent entities since
  • In 2018, the US Food and Drug Administration FDA approved a Supplemental New Drug Application for the potassium binder Veltassa with or without food[6]
  • In 2019, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received the Swiss Success Award from the non-profit organisation Swiss Biotech Association[7]
  • In 2020, Vifor Pharma sells 100% of OM Pharma to Optimus Holding Limited for CHF 435 million[8]
  • In 2020, Vifor Pharma also forms a Joint Venture agreement with Fresenius Kabi for the market in the People's Republic of China in the area of intravenous iron deficiency treatments[9]
  • In the same year, a deal with Cara Therapeutics for the commercialisation of Difelikefalin to treat CKD-aP patients has been signed.[10][11]
  • In 2021 Vifor Pharma concluded a licensing agreement for the commercialisation of sparsentan in Europe, Australia, and New Zealand.[12]
  • In the same year, Tavneos was approved in the US, Japan and the EU. Korsuva / Kapruvia reached approval in the United States and the EU.[12]
  • In November 2021, Vifor Pharma Group acquired Sanifit with its novel inhibitor of vascular calcification SNF472 for the treatment of calcific uremic arteriolopathy (CUA) and peripheral artery disease (PAD) in patients with end-stage kidney disease. On the same day, Vifor announced the acquisition of Swiss-based Inositec who develops treatments for soft tissue and vascular calcification disorders and aortic valve stenosis (AVS).[13]
  • In December 2021 CSL Limited announced it would acquire Vifor Pharma for CHF 10.9 billion (US$11.7 billion).[14] The capital raising is considered one of the ten largest secondary-market deals worldwide in 2021.[15]
  • In August 2022 the acquisition of Vifor Pharma by Australian company CSL was completed. Vifor Pharma became CSL Vifor.[16]

Activity

CSL Vifor is active in the treatment of iron deficiency and iron deficiency anaemia.[17] The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases. Iron deficiency treatments Ferinject and Injectafer were accountable for more than a third of its revenues in 2021.[3]

The dialysis segment with the Erythropoiesis-Stimulating Agents Mircera[18] (Methoxy polyethylene glycol-epoetin beta) and Retacrit (Epoetin alfa-epbx) as well as the phosphate binder Velphoro (Sucroferric oxyhydroxide) has a similarly high turnover as the iron deciency area, which also includes the orally administered treatment Maltofer (iron polymaltose). The potassium binder Veltassa (Patiromer) is the most selling treatment in the nephrology segment.[19]

CSL Vifor is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA).[20] CSL Vifor has formed collaborations with pharmaceutical companies like American Regent, Roche, Fresenius Medical Care, Fresenius Kabi[21] and Pfizer. It has also partnered with biotechs such as Akebia, Angion Biomedica, Cara Therapeutics, ChemoCentryx and Travere Therapeutics.[22]

Structure and operations

CSL Vifor is present in North and South America, Europe, the Middle East and Asia Pacific and is active in over 100 countries all around the world.[23] R&D sites of the group are located in Switzerland.[24] The company is headquartered in St. Gallen where its core manufacturing capabilities on active pharmaceutical ingredient (API) production of its iron therapies are concentrated.[25] The operational headquarters for sales, marketing, medicine and registration are located in Glattbrugg.[18] CSL Vifor maintains a research site on iron deficiency in the Bio-Technopark in Schlieren. The Zurich-based subsidiary Inositec is an ETH spin-off. Sanifit Therapeutics is based in Palma de Mallorca.[13] In China, Vifor Fresenius Kabi is among the top 10 multinational pharmaceutical companies as a market leader in clinical nutrition, anesthesia and nephrology.[21]

CSL Vifor develops, manufactures and markets pharmaceutical products.[26] The Group's businesses include CSL Vifor, focused on iron deficiency and iron deficiency anaemia, and Vifor Fresenius Medical Care Renal Pharma, focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases.[23] The second joint company of CSL Vifor with Fresenius is Vifor Fresenius Kabi focusing on marketing iron deficiency drugs in China.[27] CSL Vifor includes also Sanifit Therapeutics from Spain active in the field of calcification disorders in Chronic Kidney Disease.[28] Nephtera is a joint venture with Evotec to build a nephrology therapeutic pipeline.[29]

Therapeutic areas

Iron deficiency is a condition in which iron availability is insufficient to meet body needs. It affects one out of three women of reproductive age worldwide.[30] CSL Vifors first treatment in this area dates back to the pioneering work of pharmacist Caspar Friedrich Hausmann in 1872 in St. Gallen. Iron-deficiency anemia,[22] inflammatory bowel disease (IBD), chronic heart failure (CHF)[22] and patient blood management (PBM)[22] are conditions treated by iron-based products of CSL Vifor.

Besides Iron, the Swiss company focusses on the therapeutic areas Dialysis, Nephrology and Rare Diseases. Vifor Fresenius Medical Care Renal Pharma (VFMCRP), the joint company with Fresenius Medical Care since 2010, gives CSL Vifor access to a network of dialysis centers.[23] It is active in the treatment of chronic kidney disease (CKD),[31] chronic kidney disease-associated pruritus,[32] renal anemia[33] and hyperphosphatemia.[23]

In the therapeutic area nephrology and rare disease, CSL Vifor specializes on hyperkalemia,[23] secondary hyperparathyroidism,[34] ANCA-associated vasculitis,[25] beta-thalassemia[35] and sickle cell disease,[36] CKD-associated peripheral artery disease[25] and aortic valve stenosis,[13][25] focal segmental glomerulosclerosis,[25] IgA nephropathy[25] and cardiac surgery-associated Acute kidney injury (CSA-AKI).[22]

Products and in-Licensing

Apart from its own manufactured iron products, CSL Vifor enters partnerships and is in-licensing products at an advanced stage of development additionally to its own research and development (R&D). CSL Vifor has concluded cooperation and licensing agreements with both large pharmaceutical companies and smaller biotech companies.[25]

Commercialized Products[25]

Pipeline products[25]

  • Korsuva (Difelikefalin) (in-licensed from Cara Therapeutics)[36]
  • INS-3001[13]
  • Rayaldee (Calcifediol) (in-licensed from OPKO Health)
  • Sparsentan (in-licensed from Travere Therapeutics)
  • SNF472
  • Tavneos (Avacopan) (in-licensed from ChemoCentryx Inc.)
  • Vadadustat (in-licensed from Akebia Therapeutics)
  • Vamifeport (developed by CSL Vifor)[36]

References

  1. ^ "Der reichste Ebener aller Zeiten". Handelszeitung (in German). 2021-12-14. Retrieved 2022-05-10.
  2. ^ Kanstein, Fraiser (2022-08-02). "After delay, CSL's $11.7B deal for Vifor poised to close next week". Fiercepharma. Retrieved 2022-12-29.
  3. ^ a b Redrup, Yolanda (2022-02-18). "Vifor results show strength as CSL tender period nears end". Australian Financial Review. Retrieved 2022-02-28.
  4. ^ "Galenica says to offer $915 million for Aspreva". Reuters. Retrieved 2021-11-28.
  5. ^ "Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split". Reuters. Retrieved 2021-11-28.
  6. ^ "Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food". 2018-05-08. Retrieved 2022-11-20.
  7. ^ "Media release: Swiss biotechnology – Investments at record level and outstanding success stories". Swiss Biotech. Retrieved 2021-11-28.
  8. ^ "Vifor Pharma Group announces successful sale of OM Pharma". www.viforpharma.com. Retrieved 2020-10-04.
  9. ^ "Vifor Pharma and Fresenius Kabi form joint venture in China". 2020-02-20. Retrieved 2022-11-20.
  10. ^ "Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance". Bloomberg News. 2021-08-21. Retrieved 2022-11-20.
  11. ^ "Vifor Pharma in US$100m licence deal with Cara Therapeutics". 2020-10-21. Retrieved 2022-11-20.
  12. ^ a b "Vifor Pharma reports sustained growth in 2021". 2022-02-17. Retrieved 2022-11-20.
  13. ^ a b c d Terry, Mark (2021-11-22). "Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions". biospace.com. Retrieved 2022-02-28.
  14. ^ "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln | Reuters". Reuters.
  15. ^ Nainan, Nikhil; Koltrowitz, Silke; Murdoch, Scott (2021-12-14). "Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln". Reuters. Retrieved 2022-02-28.
  16. ^ "CSL share price climbs as $16 billion Vifor acquisition becomes effective". 2022-08-09. Retrieved 2022-11-20.
  17. ^ "Anemia Treatment Drugs: 2019 Global Market Study; Analyzed". globenewswire.com. Retrieved 2021-11-28.
  18. ^ a b "Vifor Fresenius Medical Care Renal Pharma". Swissbiotech. Retrieved 2022-05-10.
  19. ^ "Vifor Pharma reports sustained growth in 2021". Biospace. 2022-02-17. Retrieved 2022-05-10.
  20. ^ "Membership". efpia.eu. Retrieved 2021-11-28.
  21. ^ a b "Vifor Pharma and Fresenius Kabi form joint venture in China". Pharmaceutical Technology. 2020-02-20. Retrieved 2022-05-10.
  22. ^ a b c d e "Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance". Bloomberg. 2021-08-05. Retrieved 2022-05-10.
  23. ^ a b c d e "Fairness Opinion Vifor Pharma". IFBC. 2022-01-17. Retrieved 2022-05-20.
  24. ^ "Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World's First Research Professorship for Nanopharmaceutical and Regulatory Science". Businesswire. 2019-05-26. Retrieved 2022-06-28.
  25. ^ a b c d e f g h i "Vifor Pharma reports sustained growth in 2021". Biospace. 2022-02-17. Retrieved 2022-05-20.
  26. ^ Lafrenz, Carrie (2021-12-14). "CSL had eye on Vifor Pharma for a decade". Australian Financial Review. Retrieved 2022-06-28.
  27. ^ Staines, Richard (2020-02-20). "Vifor forges iron drug partnership with Fresenius in China". Pharmaphorum. Retrieved 2022-06-28.
  28. ^ "Vifor Pharma jumps further into vascular calcification field, through acquisitions". The Pharma Letter. 2021-11-22. Retrieved 2022-06-28.
  29. ^ "Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance". Australian Financial Review. 2020-03-12. Retrieved 2022-06-28.
  30. ^ Patterson, Amanda; Johnson, Jacklyn (2020-11-18). "I've been diagnosed with iron deficiency, now what?". Hippocampus. Retrieved 2022-05-20.
  31. ^ "fizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market". Biospace. 2018-07-31. Retrieved 2022-05-20.
  32. ^ "Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients". Biospace. 2022-02-25. Retrieved 2022-05-20.
  33. ^ "Vifor Pharma's IV Ferinject reduces the need for further anemia treatment in kidney disease patients". ASN-Online. 2013-07-10. Retrieved 2022-05-20.
  34. ^ "Indirect Comparison of Treatments for Secondary Hyperparathyroidism Through a Network Meta-Analysis". ASN-Online. 2020-10-22. Retrieved 2022-05-20.
  35. ^ "Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia". The Journal of Clinical Investigation. 2019-10-22. Retrieved 2019-10-22.
  36. ^ a b c McKenzie, Heather (2021-12-14). "CSL Tenders Offer to Buy Vifor Pharma for $11.7 Billion". Biospace. Retrieved 2022-05-20.

External links

  • Official website

January 26, 2023
vifor, global, specialty, pharmaceuticals, company, treatment, areas, iron, deficiency, dialysis, nephrology, rare, disease, headquartered, switzerland, consists, vifor, fresenius, medical, care, renal, pharma, vfmcrp, sanifit, therapeutics, typepublictraded, . CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency dialysis nephrology amp rare disease It is headquartered in Switzerland and consists of CSL Vifor Vifor Fresenius Medical Care Renal Pharma VFMCRP and Sanifit Therapeutics CSL ViforTypePublicTraded asSIX VIFNISINCH0364749348IndustryPharmaceuticalFounded1927 1 HeadquartersSwitzerlandAreas servedWorldwideKey peopleHerve Gisserot General Manager 2 RevenueCHF 1 75 billion 2021 3 Websitewww wbr viforpharma wbr com Contents 1 History 2 Activity 3 Structure and operations 4 Therapeutic areas 5 Products and in Licensing 6 References 7 External linksHistory EditIn 1872 Caspar Friedrich Hausmann founds a pharmacy in St Gallen In 1927 16 pharmacists establish a joint purchasing centre Collaboration Pharmaceutique SA which went on to be renamed Galenica AG in 1933 later to be renamed Vifor Pharma Ltd in 2017 In 1944 The pharmacist Rene Grosclaude founds Vifor Ltd the company produces over the counter medicines In 1983 Hausmann AG laboratories is acquired by Galenica In 1991 Vifor International Ltd is founded and takes over the work of Laboratorien Hausmann in developing new iron products In 2008 Vifor Pharma is founded following the 915 million acquisition of a Canadian company Aspreva Pharmaceutical Corporation 4 Vifor Ltd and Vifor international Ltd are integrated in Vifor Pharma In 2009 Galenica acquires OM Pharma a Swiss biotechnology company In 2010 Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma VFMCRP In 2014 Galenica is divided into two divisions Vifor Pharma and Galenica Sante In 2016 Relypsa a US based biotechnology company is purchased for 1 53 billion 5 In 2017 the IPO of Galenica Sante GALE is completed and listed on the Swiss Stock Exchange Galenica AG GALE and Vifor Pharma AG VIFN are listed as independent entities since In 2018 the US Food and Drug Administration FDA approved a Supplemental New Drug Application for the potassium binder Veltassa with or without food 6 In 2019 Vifor Fresenius Medical Care Renal Pharma VFMCRP received the Swiss Success Award from the non profit organisation Swiss Biotech Association 7 In 2020 Vifor Pharma sells 100 of OM Pharma to Optimus Holding Limited for CHF 435 million 8 In 2020 Vifor Pharma also forms a Joint Venture agreement with Fresenius Kabi for the market in the People s Republic of China in the area of intravenous iron deficiency treatments 9 In the same year a deal with Cara Therapeutics for the commercialisation of Difelikefalin to treat CKD aP patients has been signed 10 11 In 2021 Vifor Pharma concluded a licensing agreement for the commercialisation of sparsentan in Europe Australia and New Zealand 12 In the same year Tavneos was approved in the US Japan and the EU Korsuva Kapruvia reached approval in the United States and the EU 12 In November 2021 Vifor Pharma Group acquired Sanifit with its novel inhibitor of vascular calcification SNF472 for the treatment of calcific uremic arteriolopathy CUA and peripheral artery disease PAD in patients with end stage kidney disease On the same day Vifor announced the acquisition of Swiss based Inositec who develops treatments for soft tissue and vascular calcification disorders and aortic valve stenosis AVS 13 In December 2021 CSL Limited announced it would acquire Vifor Pharma for CHF 10 9 billion US 11 7 billion 14 The capital raising is considered one of the ten largest secondary market deals worldwide in 2021 15 In August 2022 the acquisition of Vifor Pharma by Australian company CSL was completed Vifor Pharma became CSL Vifor 16 Activity EditCSL Vifor is active in the treatment of iron deficiency and iron deficiency anaemia 17 The Group also has a focus on the management of conditions in nephrology cardiology and rare diseases Iron deficiency treatments Ferinject and Injectafer were accountable for more than a third of its revenues in 2021 3 The dialysis segment with the Erythropoiesis Stimulating Agents Mircera 18 Methoxy polyethylene glycol epoetin beta and Retacrit Epoetin alfa epbx as well as the phosphate binder Velphoro Sucroferric oxyhydroxide has a similarly high turnover as the iron deciency area which also includes the orally administered treatment Maltofer iron polymaltose The potassium binder Veltassa Patiromer is the most selling treatment in the nephrology segment 19 CSL Vifor is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared this includes the European Federation of Pharmaceutical Industries and Associations EFPIA 20 CSL Vifor has formed collaborations with pharmaceutical companies like American Regent Roche Fresenius Medical Care Fresenius Kabi 21 and Pfizer It has also partnered with biotechs such as Akebia Angion Biomedica Cara Therapeutics ChemoCentryx and Travere Therapeutics 22 Structure and operations EditCSL Vifor is present in North and South America Europe the Middle East and Asia Pacific and is active in over 100 countries all around the world 23 R amp D sites of the group are located in Switzerland 24 The company is headquartered in St Gallen where its core manufacturing capabilities on active pharmaceutical ingredient API production of its iron therapies are concentrated 25 The operational headquarters for sales marketing medicine and registration are located in Glattbrugg 18 CSL Vifor maintains a research site on iron deficiency in the Bio Technopark in Schlieren The Zurich based subsidiary Inositec is an ETH spin off Sanifit Therapeutics is based in Palma de Mallorca 13 In China Vifor Fresenius Kabi is among the top 10 multinational pharmaceutical companies as a market leader in clinical nutrition anesthesia and nephrology 21 CSL Vifor develops manufactures and markets pharmaceutical products 26 The Group s businesses include CSL Vifor focused on iron deficiency and iron deficiency anaemia and Vifor Fresenius Medical Care Renal Pharma focused on kidney disease patients including anaemia mineral and bone management cardio renal conditions and rare diseases 23 The second joint company of CSL Vifor with Fresenius is Vifor Fresenius Kabi focusing on marketing iron deficiency drugs in China 27 CSL Vifor includes also Sanifit Therapeutics from Spain active in the field of calcification disorders in Chronic Kidney Disease 28 Nephtera is a joint venture with Evotec to build a nephrology therapeutic pipeline 29 Therapeutic areas EditIron deficiency is a condition in which iron availability is insufficient to meet body needs It affects one out of three women of reproductive age worldwide 30 CSL Vifors first treatment in this area dates back to the pioneering work of pharmacist Caspar Friedrich Hausmann in 1872 in St Gallen Iron deficiency anemia 22 inflammatory bowel disease IBD chronic heart failure CHF 22 and patient blood management PBM 22 are conditions treated by iron based products of CSL Vifor Besides Iron the Swiss company focusses on the therapeutic areas Dialysis Nephrology and Rare Diseases Vifor Fresenius Medical Care Renal Pharma VFMCRP the joint company with Fresenius Medical Care since 2010 gives CSL Vifor access to a network of dialysis centers 23 It is active in the treatment of chronic kidney disease CKD 31 chronic kidney disease associated pruritus 32 renal anemia 33 and hyperphosphatemia 23 In the therapeutic area nephrology and rare disease CSL Vifor specializes on hyperkalemia 23 secondary hyperparathyroidism 34 ANCA associated vasculitis 25 beta thalassemia 35 and sickle cell disease 36 CKD associated peripheral artery disease 25 and aortic valve stenosis 13 25 focal segmental glomerulosclerosis 25 IgA nephropathy 25 and cardiac surgery associated Acute kidney injury CSA AKI 22 Products and in Licensing EditApart from its own manufactured iron products CSL Vifor enters partnerships and is in licensing products at an advanced stage of development additionally to its own research and development R amp D CSL Vifor has concluded cooperation and licensing agreements with both large pharmaceutical companies and smaller biotech companies 25 Commercialized Products 25 Ferinject Injectafer Ferric carboxymaltose Maltofer Iron polymaltose Mircera Methoxy polyethylene glycol epoetin beta in licensed from Roche Veltassa Patiromer Velphoro Sucroferric oxyhydroxide Venofer Iron sucrose Retacrit Erythropoiesis stimulating agent in licensed from Pfizer Pipeline products 25 Korsuva Difelikefalin in licensed from Cara Therapeutics 36 INS 3001 13 Rayaldee Calcifediol in licensed from OPKO Health Sparsentan in licensed from Travere Therapeutics SNF472 Tavneos Avacopan in licensed from ChemoCentryx Inc Vadadustat in licensed from Akebia Therapeutics Vamifeport developed by CSL Vifor 36 References Edit Der reichste Ebener aller Zeiten Handelszeitung in German 2021 12 14 Retrieved 2022 05 10 Kanstein Fraiser 2022 08 02 After delay CSL s 11 7B deal for Vifor poised to close next week Fiercepharma Retrieved 2022 12 29 a b Redrup Yolanda 2022 02 18 Vifor results show strength as CSL tender period nears end Australian Financial Review Retrieved 2022 02 28 Galenica says to offer 915 million for Aspreva Reuters Retrieved 2021 11 28 Galenica to buy biotech firm Relypsa for 1 5 billion ahead of split Reuters Retrieved 2021 11 28 Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa patiromer With or Without Food 2018 05 08 Retrieved 2022 11 20 Media release Swiss biotechnology Investments at record level and outstanding success stories Swiss Biotech Retrieved 2021 11 28 Vifor Pharma Group announces successful sale of OM Pharma www viforpharma com Retrieved 2020 10 04 Vifor Pharma and Fresenius Kabi form joint venture in China 2020 02 20 Retrieved 2022 11 20 Vifor Pharma reports strong H1 2021 growth on track to meet full year guidance Bloomberg News 2021 08 21 Retrieved 2022 11 20 Vifor Pharma in US 100m licence deal with Cara Therapeutics 2020 10 21 Retrieved 2022 11 20 a b Vifor Pharma reports sustained growth in 2021 2022 02 17 Retrieved 2022 11 20 a b c d Terry Mark 2021 11 22 Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions biospace com Retrieved 2022 02 28 Australia s CSL to buy Swiss drugmaker Vifor for 11 7 bln Reuters Reuters Nainan Nikhil Koltrowitz Silke Murdoch Scott 2021 12 14 Australia s CSL to buy Swiss drugmaker Vifor for 11 7 bln Reuters Retrieved 2022 02 28 CSL share price climbs as 16 billion Vifor acquisition becomes effective 2022 08 09 Retrieved 2022 11 20 Anemia Treatment Drugs 2019 Global Market Study Analyzed globenewswire com Retrieved 2021 11 28 a b Vifor Fresenius Medical Care Renal Pharma Swissbiotech Retrieved 2022 05 10 Vifor Pharma reports sustained growth in 2021 Biospace 2022 02 17 Retrieved 2022 05 10 Membership efpia eu Retrieved 2021 11 28 a b Vifor Pharma and Fresenius Kabi form joint venture in China Pharmaceutical Technology 2020 02 20 Retrieved 2022 05 10 a b c d e Vifor Pharma reports strong H1 2021 growth on track to meet full year guidance Bloomberg 2021 08 05 Retrieved 2022 05 10 a b c d e Fairness Opinion Vifor Pharma IFBC 2022 01 17 Retrieved 2022 05 20 Pioneering Project for Pharmaceutics Vifor Pharma and the University of Basel are Jointly Establishing the World s First Research Professorship for Nanopharmaceutical and Regulatory Science Businesswire 2019 05 26 Retrieved 2022 06 28 a b c d e f g h i Vifor Pharma reports sustained growth in 2021 Biospace 2022 02 17 Retrieved 2022 05 20 Lafrenz Carrie 2021 12 14 CSL had eye on Vifor Pharma for a decade Australian Financial Review Retrieved 2022 06 28 Staines Richard 2020 02 20 Vifor forges iron drug partnership with Fresenius in China Pharmaphorum Retrieved 2022 06 28 Vifor Pharma jumps further into vascular calcification field through acquisitions The Pharma Letter 2021 11 22 Retrieved 2022 06 28 Vifor Pharma Group Reports Strong Growth in 2019 Exceeding Raised Guidance Australian Financial Review 2020 03 12 Retrieved 2022 06 28 Patterson Amanda Johnson Jacklyn 2020 11 18 I ve been diagnosed with iron deficiency now what Hippocampus Retrieved 2022 05 20 fizer s Retacrit the First Erythropoietin Stimulating Agent to be FDA Approved Not Likely to See Rapid Adoption in the US Dialysis Market Biospace 2018 07 31 Retrieved 2022 05 20 Kapruvia receives positive CHMP opinion for the treatment of moderate to severe pruritus in hemodialysis patients Biospace 2022 02 25 Retrieved 2022 05 20 Vifor Pharma s IV Ferinject reduces the need for further anemia treatment in kidney disease patients ASN Online 2013 07 10 Retrieved 2022 05 20 Indirect Comparison of Treatments for Secondary Hyperparathyroidism Through a Network Meta Analysis ASN Online 2020 10 22 Retrieved 2022 05 20 Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of b thalassemia The Journal of Clinical Investigation 2019 10 22 Retrieved 2019 10 22 a b c McKenzie Heather 2021 12 14 CSL Tenders Offer to Buy Vifor Pharma for 11 7 Billion Biospace Retrieved 2022 05 20 External links EditOfficial website Retrieved from https en wikipedia org w index php title CSL Vifor amp oldid 1132150588, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.